What is DBVT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DBVT?

P/E (TTM) is n/a and 52-week range is $1.53 to $4.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DBVT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DBVT?

The company profile lists revenue (TTM) near $2M, net income (TTM) near -$5.76B, EPS (TTM) near -$1.07 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Dbv Technologies SA based, and what identifiers does Chartloom list?

The company context section lists headquarters in Chatillon, Auvergne-Rhone-Alpes, FR, 62.8M shares outstanding, ISIN FR0010417345 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Dbv Technologies SA

$DBVT

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 125 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

Employees

125

Website

www.dbv-technologies.com/

IPO

2012-03-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NYSE EURONEXT - EURONEXT PARIS

ISIN

FR0010417345

Headquarters

Chatillon, Auvergne-Rhone-Alpes, FR

Shares outstanding

62.8M

NAICS sector

Manufacturing

Institutional ownership

53.55%

Browse other companiesFree AI scores and summaries for more stocks

Dbv Technologies SA (DBVT) Stock Analysis & Quote